Merck & Co
Address: 2025 E Scott Ave,, Rahway, New Jersey. NJ 07065About Us
Our rich history of discovery and innovation began more than 125 years ago and continues today. Through the years, our researchers have helped to find new ways to treat and prevent illness in people and animals around the world. We've done great things in the past. Today, we're doing great things for the future
Sectors
- Proprietary Research & Manufacture
Categories
- Finished Dosage
- Regulatory Support
- Corporate Headquarters
- Licensing
- Research and Development Centre
- Vaccine Products
- Vaccine Manufacturing
- Oncology Products
- immuno-oncology
- Anti-Infection Products
- Infection Prevention
- Cardiovascular Products
- Immunology
- Immunotherapy
Certifications
- GMP-USA-FDA-Inspected
Key Contacts
Ben Thorner Senior Vice President and Head, / MRL Business Development & Licensing / mrlbdlm@merck.comNews
Variational AI, Merck Partner on Generative AI Project
VANCOUVER, British Columbia — Variational AI, developer of the Enki™ generative artificial intelligence (AI) platform for drug discovery, today announced a project with Merck Research Labs supported by the CQDM Quantum Leap program.
“We are pleased to announce Merck as an early-access user of our Enki™ Platform,” said Handol Kim, CEO, Variational AI. “Merck will evaluate Enki’s ability to generate novel small molecules on targets of their choosing. We built and trained Enki™ as a foundation model that generates novel, selective, and synthesizable lead-like structures. It designs novel molecules how other generative AI foundation models like DALL-E and Midjourney create novel images based on text prompts. In our case, a target product profile (TPP) is used as the series of prompts to describe the molecules in the language of chemistry. Enki™ then rapidly generates structures that meet the TPP.”
Merck's first ever AI solution has more than 60 billion possibilities for successful drug properties
Science and technology giant, Merck, has launched its first software-as-a-service (SaaS) platform that it says bridges the gap between virtual molecule design and real-world manufacturability.
Merck signs a $1B-plus supply deal for COVID pill with Japan
KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that the Japanese government will purchase, upon authorization or approval, approximately 1.6 million courses of molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine. Merck is developing molnupiravir in collaboration with Ridgeback Biotherapeutics. Merck’s applications for the potential authorized use of molnupiravir are under review by Japan’s Pharmaceuticals and Medical Devices Agency, the U.S. Food and Drug Administration, and the European Medicines Agency. Molnupiravir is authorized in the United Kingdom for the treatment of mild-to-moderate COVID-19 in adults with a positive SARS-CoV-2 diagnostic test and who have at least one risk factor for developing severe illness.
Merck’s KEYTRUDA® (pembrolizumab) Melanoma Compared to Placebo
KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the first results from the Phase 3 KEYNOTE-716 trial, in which adjuvant treatment with KEYTRUDA, Merck’s anti-PD-1 therapy, showed a statistically significant and clinically meaningful improvement in recurrence-free survival (RFS), the trial’s primary endpoint, compared to placebo in patients with resected high-risk stage II melanoma; KEYTRUDA is the first anti-PD-1 therapy to demonstrate this.
Merck to Acquire Acceleron Pharma Inc.
KENILWORTH, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Acceleron Pharma Inc. (Nasdaq: XLRN), a publicly traded biopharmaceutical company, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Acceleron for $180 per share in cash for an approximate total equity value of $11.5 billion.
Merck ‘evaluating global footprint’ with $1.2bn manufacturing restructure
Cancer drug Keytruda drives profit at Merck
Pharmaceutical giant Merck picks London for new HQ
Merck's Keytruda resumes regulatory hot streak with stomach cancer approval
Friday, U.S. regulators gave the drug a go-ahead as a treatment for two types of recurrent or advanced gastric cancer in patients who've received at least two prior rounds of therapy. The accelerated approval comes based on tumor response rate and durability of response data, Merck said.
Merck sales disappoint as Januvia, Remicade fall short
Merck cautious on 2016 as sales of top medicines lag
Job Vacancies
The successful candidate will have the opportunity to apply their enthusiasm and technical skills as a member of a multidisciplinary team supporting the operation of pharmaceutical, biopharmaceutical, vaccine product manufacturing facilities.
Source: The Partnership Tree | https://www.pharmaservicesdirectory.com